No Data
Brightgene bio-medical technology co.,ltd. (688166.SH): Dydrogesterone tablets and its active pharmaceutical ingredient, as well as the active pharmaceutical ingredient of dexmedetomidine tartrate, have been approved for marketing.
brightgene bio-medical technology co.,ltd. (688166.SH) announced that its wholly-owned subsidiary, brightgene pharmaceutical (suzhou) co., ltd...
Express News | Brightgene bio-medical technology co.,ltd.: Subsidiary obtained pharmaceutical registration certificate and listing application approval.
Brightgene Bio-Medical Technology Co.,Ltd. (688166): Dual-target GLP1/GIP innovative drug has promising future; first recommended to buy.
Active pharmaceutical ingredient and preparation business have stable growth. The company implements a strategy that integrates active pharmaceutical ingredients and preparations, combines generic drugs with innovative drugs, and focuses on first-to-market generics, challenging generics, specialty active pharmaceutical ingredients, complex preparations, and original new drugs. The company focuses on specialty active pharmaceutical ingredients and pharmaceutical intermediates.
Brightgene Bio-Medical Technology Co.,Ltd. (688166) quarterly review: excellent clinical data performance comprehensive layout overseas.
The company released the third-quarter report of 2024, with a revenue of 0.319 billion yuan in 2024Q3, a decrease of 2.52% year-on-year, and a non-GAAP net income attributable to the parent of 68.39 million yuan, a decrease of 17.34% year-on-year. The revenue for the first three quarters of 2024 was 9.77 billion.
Borui Pharmaceutical (688166): The clinical progress of BGM0504 is relatively rapid, and the inhalation formulation is progressing smoothly
Results increased steadily in the first three quarters of 2024, and BGM0504 and inhalation formulations progressed smoothly. In the first three quarters of 2024, the company achieved revenue of 0.977 billion yuan (+6.77% compared to the same period; the following are all year-on-year ratios), which is net for mother
Third Quarter Report 2024
No Data
No Data